Cosibelimab
Class
Targeted therapy
Subclass
Anti-PD-L1 monoclonal antibodies
Substance name
Cosibelimab, cosibelimab-ipdl
Brand names
Unloxcyt®
Common formulations
Solution for injection
Dosage and administration
Adults patients
Treatment of cutaneous SCC • Metastatic or locally advanced, ineligible for curative surgery or radiation
Indications for use
Labeled indications
Adults
Safety risks
Warnings and precautions
GvHD, hepatic veno-occlusive disease
Immune-mediated adverse reactions
Infusion-related reactions
Specific populations
Renal impairment
CrCl ≥ 15 mL/min
CrCl < 15 mL/min
Renal replacement therapy
Any modality
Hepatic impairment
Child-Pugh A (mild)
Child-Pugh B (moderate)
Child-Pugh C (severe)
Pregnancy and breastfeeding
Pregnancy
All trimesters
Breastfeeding
Do not use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Uncommon < 1%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource